Algernon Pharmaceuticals has announced its plans to launch its first Phase 2 clinical trial evaluating one of two repurposed compounds — NP-120 for the treatment of idiopathic pulmonary fibrosis (IPF) or NP-178 for inflammatory bowel disease (IBD) — in the second quarter of 2020. This follows…
Algernon Plans Launch of First Phase 2 Trial on Repurposed IPF or IBD Compound by Mid-2020
Patients with idiopathic pulmonary fibrosis (IPF) in Canada face challenges in equal access to quality healthcare services at the national level, with drastic differences between provinces, according to the findings of a new report from the Canadian Pulmonary Fibrosis Foundation (CPFF) and Hoffmann-La Roche. The report, titled…
Healthy eating is a popular topic on the Pulmonary Fibrosis News Forums. Members discuss their attempts to promote optimal pulmonary wellness by improving their eating habits. They also share what foods they avoid because of side effects and what foods help them feel better. Someone once said, “Eat…
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in care in a recent survey of people with pulmonary fibrosis (PF) and their healthcare providers. The survey results were discussed in the journal ERJ Open Research in a study,…
It’s hard to be open with people when you’re going through a crisis, particularly one with many uncertainties. A recent conversation with a friend got me thinking about the vulnerable act of sharing trauma. My friend is preparing for a painful and risky surgery to remove uterine…
UCLA Health has launched a $20-million fundraising initiative to support the creation of a new research and treatment center for advanced lung diseases, including idiopathic pulmonary fibrosis (IPF), at the David Geffen School of Medicine at UCLA. The Lung Health Research Accelerator Fund…
Cold and flu season begins in October and peaks between December and February, according to the Centers for Disease Control and Prevention. We’re in the midst of the season, and I feel under pressure to do everything I can to remain as healthy as possible. Those of us who…
Roche has acquired Promedior, a biotechnology company, and its full portfolio of molecules to possibly treat fibrotic diseases. The portfolio includes PRM-151, a lead therapy candidate for  idiopathic pulmonary fibrosis (IPF) advancing in clinical testing. PRM-151 is a synthetic engineered version of pentraxin-2, a protein that is able to…
A model of the human lung constructed with the help of tissue samples from 10 idiopathic pulmonary fibrosis (IPF) patients details changes in gene activity that precede evident fibrosis, a study reports. This model is a sort of genetic roadmap to IPF progression that may help researchers find treatments for…
When learning to live with idiopathic pulmonary fibrosis (IPF), mental health is an elephant in the room. Too often, it is ignored. Although it is becoming more prevalent among hospital care plans, it needs to be discussed more frequently. Learning to live with IPF has been the hardest thing…
